Bank of America: The new drug approved by Lilly has the potential to become a leader in the GLP-1 field.

Analysts at Bank of America stated that the approval of Novo Nordisk's oral weight-loss drug may give it a leading position in the competition for GLP-1. These analysts said, "We believe that with its ease of use, this product will become the preferred oral GLP-1 product." The approval of the pill, named Foundayo, came slightly earlier than expected by these analysts. They believe that investors will be watching to see if Foundayo will cannibalize the demand for Novo Nordisk's other weight-loss drug, Zepbound. The analysts have not raised their estimates for Novo Nordisk's annual revenue, but have increased their target price by $1 to $1,294.